Could Tirzepatide Replace CPAP Machines for Obesity-Related Sleep Apnea? | Research

The takeaway

Tirzepatide, a dual GLP-1/GIP receptor agonist, significantly reduces body weight, sleep apnea severity (AHI), and inflammation in obesity-related OSA, emerging as a potential pharmacologic alternative to CPAP therapy.

Clinically significant AHI reduction
Tirzepatide reduced the apnea-hypopnea index — the key measure of sleep apnea severity — alongside body weight and systemic inflammation in the SURMOUNT-OSA trials.

What the researchers found

Evidence from the SURMOUNT-OSA and related trials shows tirzepatide produced clinically significant reductions in body weight, apnea-hypopnea index (AHI — the primary measure of sleep apnea severity), and systemic inflammation in patients with obesity-related OSA.

Beyond improving sleep apnea itself, tirzepatide showed additional benefits for sleep quality and cardiovascular risk factors. By targeting both metabolic and structural contributors to OSA (weight loss reduces airway obstruction while metabolic improvements address systemic inflammation), tirzepatide addresses the condition from multiple angles simultaneously.

Why it matters

OSA affects an estimated 1 billion people worldwide, and CPAP adherence is notoriously poor — many patients abandon the device. A pharmacologic treatment that addresses the root cause (obesity) while directly improving sleep apnea severity could transform OSA management. Tirzepatide's ability to also reduce inflammation and cardiovascular risk factors addresses the full spectrum of OSA-related health consequences.

How the study worked

Narrative review using structured search of PubMed, Google Scholar, and Scopus for English-language articles published through May 2024. Search terms included tirzepatide, obstructive sleep apnea, OSA, and GLP-1 agonist. Clinical trials, systematic reviews, and observational studies focusing on tirzepatide's role in OSA or obesity were included and thematically analyzed.

What this study cannot tell us

This is a narrative review, not a systematic review or meta-analysis. The long-term effects of tirzepatide on OSA are unknown — weight loss medications may need to be continued indefinitely. The review was limited to studies through May 2024 and may not capture the latest data. Tirzepatide may not help patients with non-obesity-related OSA. Cost and access barriers could limit real-world adoption. Head-to-head comparisons with CPAP are limited.

How to read the evidence

This is a narrative review drawing primarily from the SURMOUNT-OSA randomized clinical trial data. The underlying trial evidence is strong (RCT), but this review format does not include systematic risk-of-bias assessment or quantitative synthesis.

When this study was published

Published in 2025 with literature search through May 2024, this review captures the initial SURMOUNT-OSA trial results that have made tirzepatide a leading candidate for pharmacologic OSA treatment.

The bigger picture

The expanding indications for GLP-1-based therapies continue to reshape medicine. Following diabetes, obesity, and cardiovascular disease, sleep apnea is the latest condition where these drugs show significant benefit. The SURMOUNT-OSA trial data contributed to tirzepatide receiving regulatory attention for OSA, potentially making it the first pharmacologic treatment specifically for this condition. This fits into a broader trend of incretin-based drugs addressing the systemic consequences of obesity.

Questions still open

Will tirzepatide's sleep apnea benefits persist long-term, or will they reverse if the medication is stopped?
Can tirzepatide fully replace CPAP for severe OSA, or is it better suited as adjunctive therapy?
How will the cost of long-term tirzepatide use compare to CPAP therapy for OSA management?

Common questions

Could a weight loss injection replace CPAP machines for sleep apnea?

Evidence from clinical trials suggests tirzepatide significantly improves sleep apnea by addressing its root cause — obesity. While it may not fully replace CPAP for all patients (especially those with severe OSA), it could be an effective alternative for patients who can't tolerate CPAP or a complementary treatment. The drug also improves cardiovascular risk factors and inflammation associated with OSA.

How does tirzepatide help sleep apnea?

Tirzepatide works in two main ways: (1) significant weight loss reduces the fatty tissue around the airway that causes obstruction during sleep, and (2) its anti-inflammatory effects may improve the systemic inflammation that worsens OSA. By addressing both the structural and metabolic contributors to sleep apnea, it provides comprehensive benefits beyond just weight loss.

Read the original research

Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea.

World journal of experimental medicine, 15(4), 109762

View on PubMed ↗Publisher’s paper ↗

Citation

Bajpai, Jyoti; Saxena, Mehul; Agarwal, Utkarsh; Pradhan, Akshyaya. (2025). Dual incretin analogue tirzepitide - SURMOUNTing the challenge of obesity induced obstructive sleep apnea.. World journal of experimental medicine, 15(4), 109762. https://doi.org/10.5493/wjem.v15.i4.109762